hematological malignancies
Conditions
Interventions
Thymoglobulin (rabbit ATG), 1mg/kg, day-2, -1
Sponsors
North Japan Hematology Study Group (NJHSG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are eligible for allogeneic stem cell transplantation (a) acute leukemia: CR1 or CR2 (b) lymphoma: PR or CR (c) MDS: IPSS int-2 or high; WPSS high or very high 2. Age: 16-65 years old 3. Patients who have HLA-matched related or unrelated PBSCT donor 4. Donor age: 12-65 years old 5. Performance status: 0-2 6. Patients with adequate physical function (Cardiac, Hepatic, Renal, Pulmonary).
Exclusion criteria
Exclusion criteria: 1. Patients who are positive for HBs antigen or HIV antibody. 2. Patients with severe mental illness 3. Women who are pregnant, of childbearing potential, or lactating. 4. Patients with active other malignancies. 5. Patients with active infectious disease. 6. Patients who had a history of myocardial infarction, or who needed treatment for heart failure within 1 year. 7. Patients with cirrhosis 8. Obese patients (body mass index [BMI; 35 or greater]) 9. Patients with arrhythmia (CTCAE Grade 3 or more) 10. Patients who experienced serious hypersensitivity or anaphylaxis to antithymocyte globulin. 11. Patients who are not eligible for this study at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidences of CMV infection, hemorrhagic cystitis, and PTLD at 1 year | — |
Countries
Japan
Contacts
Public ContactSugita Junichi
Hokkaido University Hospital Department of Hematology
Outcome results
None listed